

Titolo	A Phase 3, Double-Blind, Randomized, Placebo- Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD(-) Acute Myeloid Leukemia
Codice studio	AC220-168
Patologia:	Leucemia mieloide acuta
Tipo di Studio:	Interventistico
Tipologia	Profit
Fase:	3
Principali criteri di inclusione:	- Newly diagnosed, morphologically documented primary AML - Creatinine clearance >50 mL/min
Principali criteri di esclusione:	- Diagnosis of APL or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis); - Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms or autoimmune/rheumatologic conditions - Diagnosis of AML secondary to myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others - newly diagnosed AML with <i>FLT3</i>-ITD mutations (<i>FLT3</i>-ITD [+]) present at $\geq 5\%$ VAF (or ≥ 0.05 SR)
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it